

MHRA

151 Buckingham Palace Road London SW1W 9SZ United Kingdom

mhra.gov.uk

MR. K K Penugonda MACLEODS PHARMACEUTICALS LIMITED G-2 MAHAKALI CAVES ROAD SHANTI NAGAR, ANDHERI EAST MUMBAI IN-400 093 INDIA

28/06/2016

Dear MR. Penugonda,

GRANT / RENEWAL OF MARKETING AUTHORISATION

Our Reference:

PL 34771/0174 - 0001

Your Reference:

34771

Product:

Olmesartan 40mg film-coated Tablets

Type of Procedure:

Decentralised

Submission Type:

Initial

Submission Category:

Abridged

EU Procedure Number (if applicable): ES/H/0356/003/DC

The Licensing Authority agrees to the grant or renewal of the marketing authorisation for the above submission on the basis of the data provided. This includes any replacement and amendment of the original dossier.

In line with Article 23a of Directive 2001/83/EC as amended, the Marketing Authorisation Holder should submit notification of the actual date of marketing of the product to the Competent Authority. This notification should be provided by email to the following address: sunsetclause@mhra.gsi.gov.uk.

The formal documents are enclosed. These constitute evidence of authorisation. If you consider them to contain information that is incorrect or not in accordance with the dossier, please return immediately indicating any errors.

All Marketing Authorisations are subject to standard provisions contained in current medicines regulations full details of which are published on the MHRA website:

http://www.mhra.gov.uk/Howweregulate/Medicines/Licensingofmedicines/Informationforlicenceapplicants/Provisionsto whichthemarketingauthorisationisgranted/index.htm

Yours sincerely,

Ahsana Israel



The Medicines for Human Use (Marketing Authorisations etc.) Regulations, SI 1994/3144, as amended.

GRANT / RENEWAL OF MARKETING AUTHORISATION

Product: Olmesartan 40mg film-coated Tablets

Submission Type: Initial

Granted to: MACLEODS PHARMA UK LIMITED

WYNYARD PARK HOUSE

WYNYARD AVENUE, WYNYARD

BILLINGHAM TS22 5TB

UNITED KINGDOM

This Marketing Authorisation, under the above reference number is hereby granted / renewed in respect of the product named above. The Summary of Product Characteristics of the product is set out in the attached document.

The application is subject to the further provisions set out or referred to in the above Regulations.

This Marketing Authorisation, as now granted / renewed, unless previously revoked, will continue in force until the expiry date (if applicable) given below.

Grant Date:

28/06/2016

Date of Expiry:

05/06/2021

Ahsana Israel

A person authorised to sign on behalf of the Secretary of State for Health

PL 34771/0174 - 0001

Medicines and Healthcare Products Regulatory Agency